Oncology and Immuno-Oncology INSIGHTS


How Tumor Cells Escape T Cells

Immunogenic tumor cells often display protein antigens at their surface, which can be recognized by T cells and serve as a signal for T cells to attack the tumor. However, one long-standing paradox is that tumor-specific T cells often co-exist with the tumor cells. If a T cell has already recognized the tumor cells, why can't the T cell kill them at an early stage? How T...

Read More

Webinar review: Patient-Derived Xenografts on Humanized Mice

Dr. Jens Hoffmann of EPO presented a webinar highlighting new data on preclinical immuno-oncology research using humanized models. The growth in immuno-oncology (IO) research has created a need for more relevant models. The IO field includes many types of drugs, including: genetically engineered immune cells such as CAR-T cells various antibody-based therapies such as antibody-drug conjugates (ADCs) and bi-specific T cell engagers (BITEs) oncolytic viruses and bacteria...

Read More

Current Liquid Biopsy Landscape

There are over 1.7 million new cancer diagnoses each year in the US alone1. While recent advances in immuno-oncology and personalized medicine have the potential to decrease cancer deaths, there is still a lack of commonly-used early diagnostic tests to detect the presence of cancer before the patient experiences any physiological symptoms. Liquid Biopsies for Early Detection Research into liquid biopsies as a tool for early cancer...

Read More

Modelling Autophagy in Cellular Processes

Autophagy in Cellular Processes Autophagy is derived from Greek and means self(auto)-eating(phagy). This process occurs in all eukaryotic cell types that contain a lysosomal compartment. In fact, basal autophagy contributes to long-lived protein degradation, organelle turnover in the cytoplasm, and the recycling of macromolecules to maintain bioenergetics1. The purpose of autophagy is not solely the simple elimination of materials, but rather the dynamic recycling of cellular components...

Read More

Nobel Awarded to Immuno-Oncology Pioneers

The 2018 Nobel Prize for Medicine was awarded to James P. Allison and Tasuku Honjo for their contributions in the field of Immuno-Oncology. The Immuno-Oncology revolution has improved quality of life and decreased cancer mortality rates, though cancer remains the second leading cause of death worldwide. Immuno-Oncology Databases A variety of models played key roles in the development of cancer therapies, such as xenograft and syngeneic mouse...

Read More

Liver Awareness Month

October marks National Liver Awareness month. Estimates for the global burden of chronic liver disease range from 50 million to over 100 million affected individuals. According to the Centers for Disease Control and Prevention (CDC), from 2000 — 2015 there was a 31% increase in deaths from chronic liver disease. Numerous diseases ranging from liver cancer to non-alcoholic fatty liver disease (NAFLD) to hepatitis pose an increasing...

Read More

2018 Nobel Prize in Physiology or Medicine Awarded to Two Immunologists

Source: Karolinska Institutet On Monday, October 1, 2018 the Nobel Committee announced the recipients of this year's Nobel Prize in Physiology or Medicine. The two Nobel laureates were James P. Allison — a professor and immunologist from MD Anderson Cancer Center — and Tasuku Honjo — an immunologist from Kyoto University. Both researchers split the prize evenly for their pioneering discoveries relating to "cancer therapy inhibition of...

Read More

Breast Cancer Awareness Month

October is National Breast Cancer Awareness Month. There is a lot to be excited about this year as mortality rates continue to drop for major cancer types, including breast cancer. Between 1989 and 2015 deaths from breast cancer specifically declined 39%, a decline American Cancer Society attributes to "improvements in early detection." There's still work to be done, however. An estimated 270,000 new cases of breast cancer...

Read More

Pancreatic Cancer Microbiome Suppresses Immune Responses

Alterations in the microbiome have an acknowledged role in cancer pathology1,2. Earlier this year, however, researchers at New York University published a manuscript3 connecting the pancreatic microbiome to cancer progression. In this report, Pushalkar et al. demonstrate that the endogenous microbiome of the pancreas can drive immunosuppressive conditions in humans and mice, which creates a pro-tumorigenic state. Treatment regimens that include modulating the microbiome show promise for...

Read More

Webinar: Estrogen-Related Effects in Breast Cancer Xenograft Models

Breast cancer xenograft models are often treated with supplemental estrogen, but this can induce a range of adverse effects on immunodeficient mouse models including impaired urinary tract function and skin problems. Failure to control for these strain-dependent effects can seriously impact the reproducibility of preclinical research — or lead to early termination of your experiment due to their severity. In a recent webinar, Pharmatest — a contract...

Read More